Your browser is no longer supported. Please, upgrade your browser.
Settings
CANF Can-Fite BioPharma Ltd. daily Stock Chart
CANF [NYSE]
Can-Fite BioPharma Ltd.
Index- P/E- EPS (ttm)-4.80 Insider Own- Shs Outstand44.88M Perf Week1.74%
Market Cap131.49M Forward P/E- EPS next Y-4.05 Insider Trans- Shs Float1.05M Perf Month-43.11%
Income- PEG- EPS next Q-0.15 Inst Own21.13% Short Float8.20% Perf Quarter-84.12%
Sales3.49M P/S37.71 EPS this Y93.50% Inst Trans- Short Ratio0.37 Perf Half Y-84.62%
Book/sh2.13 P/B1.38 EPS next Y-1250.00% ROA- Target Price30.00 Perf Year-84.50%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.66 - 25.95 Perf YTD-84.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.90% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low8.27% ATR0.43
Employees7 Current Ratio- Sales Q/Q-52.70% Oper. Margin- RSI (14)29.33 Volatility4.23% 17.62%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.14 Prev Close2.93
ShortableYes LT Debt/Eq- EarningsJun 27 BMO Payout- Avg Volume231.39K Price2.88
Recom- SMA20-3.40% SMA50-47.12% SMA200-80.88% Volume31,842 Change-1.71%
Aug-11-17Initiated Maxim Group Buy $7
Oct-19-16Resumed ROTH Capital Buy
Aug-29-16Resumed Rodman & Renshaw Buy $6
Nov-30-15Reiterated H.C. Wainwright Buy $4 → $6
Mar-31-15Reiterated H.C. Wainwright Buy $7 → $3
Mar-30-15Downgrade ROTH Capital Buy → Neutral $20 → $2.40
Dec-29-14Reiterated ROTH Capital Buy $28 → $20
Nov-18-14Initiated H.C. Wainwright Buy $7
Jun-04-19 07:00AM  Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019 Business Wire
Jun-03-19 07:00AM  Findings from Can-Fites Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session Business Wire
May-29-19 07:00AM  Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update Business Wire
May-24-19 01:46PM  Secondary Offerings Put A Pause On May's Momentum Benzinga
May-23-19 07:00AM  The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin Business Wire -8.07%
May-20-19 02:06PM  Can-Fite BioPharma Announces $6 Million Registered Direct Offering GlobeNewswire -36.70%
11:52AM  Can-Fite Abstract Selected For Liver Conference Benzinga
07:00AM  Can-Fites Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA) Business Wire
May-06-19 07:00AM  Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson Business Wire
May-01-19 04:05PM  Can-Fite Announces ADS Ratio Change Business Wire -12.58%
Apr-15-19 07:00AM  Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea Business Wire
Apr-10-19 07:07AM  Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting Business Wire
Apr-02-19 09:00AM  Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering Business Wire -26.42%
Mar-29-19 04:30PM  Can-Fite Files Annual Report for the Year Ended December 31, 2018 Business Wire
Mar-28-19 07:00AM  Can-Fite Reports 2018 Financial Results & Provides Clinical Update Business Wire +6.19%
Mar-26-19 07:00AM  Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson Business Wire -27.83%
Mar-20-19 02:15PM  Four Marijuana Stocks on the Rise on Wednesday ACCESSWIRE +9.76%
Feb-27-19 07:00AM  Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo Business Wire
Feb-25-19 07:00AM  Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication Business Wire
Feb-04-19 09:30AM  Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19) ACCESSWIRE
07:00AM  Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug Business Wire
Jan-30-19 09:35AM  4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19) ACCESSWIRE +5.31%
07:00AM  Can-Fites Drugs Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal Business Wire
Jan-24-19 07:30AM  Can-Fite BioPharma CEO Letter to Shareholders Business Wire
Jan-18-19 08:00AM  Can-Fite BioPharma Announces Registered Direct Offering Business Wire -7.69%
Jan-08-19 08:00AM  Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent Business Wire
Jan-03-19 08:02AM  Can-Fite to Participate in the Biotech Showcase 2019 and BIO One-on-One Partnering@ JPM 2019 During the JP Morgan Healthcare Conference Business Wire
Dec-10-18 07:00AM  Can-Fite Enters Into Collaboration Agreement to Explore Namodenosons Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC Business Wire
Nov-30-18 07:00AM  Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update Business Wire
Nov-20-18 07:00AM  Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert Business Wire
Oct-31-18 07:00AM  Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19 Business Wire -8.21%
Oct-25-18 07:00AM  Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference Business Wire
Oct-18-18 07:00AM  Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018 Business Wire
Sep-12-18 07:00AM  Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD) Business Wire
Sep-04-18 07:00AM  Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year Business Wire +5.87%
Aug-31-18 07:00AM  Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update Business Wire
Aug-29-18 07:00AM  Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 Business Wire
Aug-21-18 07:00AM  Can-Fite Announces Enrollment of First Patient in its Comfort Phase III Trial of Piclidenoson in Psoriasis Business Wire +5.16%
Aug-07-18 09:14AM  Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China Business Wire -5.43%
Aug-06-18 05:54AM  Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical Business Wire +10.26%
05:19AM  BRIEF-China Medical System Holdings Says It Signed License, Collaboration & Distribution Agreement Reuters
Jul-17-18 08:56AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug Business Wire
Jul-02-18 09:10AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer Business Wire
Jun-19-18 07:00AM  Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial Business Wire +8.13%
Jun-13-18 08:55AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Jun-11-18 09:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson Business Wire
Jun-01-18 07:00AM  Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update Business Wire +6.37%
Apr-25-18 07:00AM  Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research' Business Wire
Apr-13-18 07:30AM  Wired News CymaBay to Present Positive Results from Phase-2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at the EASL Liver Meeting 2018 ACCESSWIRE
Apr-09-18 07:00AM  Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL) Business Wire
Mar-28-18 07:00AM  Can-Fite to Present at the MicroCap Conference Business Wire
Mar-23-18 07:00AM  Can-Fite Reports 2017 Financial Results & Provides Clinical Update Business Wire
Mar-14-18 07:00AM  Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference Business Wire
Mar-09-18 09:00AM  Can-Fite BioPharma Announces $5 Million Registered Direct Offering Business Wire -19.55%
Mar-06-18 07:00AM  Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference Business Wire
Mar-05-18 07:00AM  Can-Fite to Present at the Inaugural LD Micro Virtual Conference Business Wire
Feb-28-18 09:25AM  Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson Business Wire +6.21%
Feb-22-18 08:00AM  Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile Business Wire -5.46%
Feb-12-18 07:00AM  Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson Business Wire +7.43%
Jan-31-18 07:00AM  Can-Fite to Present at BIO CEO & Investor Conference Business Wire
Jan-25-18 07:00AM  Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries Business Wire +18.42%
Jan-11-18 07:00AM  Can-Fite 12 Months' Activities & Milestones for 2018 Business Wire -5.70%
Jan-08-18 07:40AM  Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings Business Wire +6.41%
Jan-03-18 07:00AM  Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH Business Wire
Dec-25-17 09:17AM  Can-Fite BioPharma Ltd. :CANF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-18-17 07:00AM  Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson Business Wire +13.85%
Dec-13-17 07:50AM  Wired News ADMA Files Biologics License Application for Its Third Plasma Collection Center ACCESSWIRE
Nov-27-17 07:30AM  Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update Business Wire
07:00AM  Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson Business Wire
Nov-17-17 07:00AM  Can-Fites Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma Business Wire
Oct-30-17 09:50AM  Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis Business Wire
Oct-17-17 07:00AM  Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis Business Wire
Oct-16-17 07:00AM  Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C. Business Wire
Oct-09-17 07:00AM  Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017 Business Wire
Oct-06-17 09:08AM  Can-Fite BioPharma Ltd. :CANF-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-25-17 07:00AM  Earnings Review and Free Research Report: Can-Fites Revenue Increased 25% ACCESSWIRE
Sep-18-17 07:00AM  Can-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy Business Wire
Sep-01-17 07:00AM  Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update Business Wire +7.19%
Aug-25-17 07:50AM  Featured Company News Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South Korea ACCESSWIRE
Aug-23-17 07:00AM  Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea Business Wire
Aug-09-17 07:00AM  Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer Business Wire
Aug-07-17 07:00AM  Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson Business Wire -7.56%
Jul-17-17 07:00AM  Can-Fites Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting Business Wire
Jun-15-17 07:00AM  Can-Fite to Participate in Bio International Convention in San Diego on June 19-22, 2017 PR Newswire
Jun-08-17 07:00AM  Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis PR Newswire
Jun-05-17 07:00AM  Can-Fite Establishes Clinical Advisory Board for NAFLD/NASH PR Newswire
Jun-01-17 07:00AM  New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017 PR Newswire
May-30-17 07:00AM  Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update PR Newswire
May-16-17 07:00AM  Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study PR Newswire
May-03-17 07:00AM  Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH PR Newswire
Apr-25-17 07:00AM  Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board PR Newswire
Mar-31-17 07:00AM  Can-Fite Reports 2016 Financial Results & Provides Clinical Update PR Newswire
Feb-28-17 07:00AM  New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis PR Newswire
Feb-23-17 11:00AM  CANF: Ready to Start Two Phase III Trials in 2017 Zacks Small Cap Research
Feb-08-17 07:00AM  Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis PR Newswire
Jan-19-17 07:29AM  Can-Fite BioPharma Announces $5 Million Registered Direct Offering PR Newswire
Jan-09-17 07:00AM  Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017 PR Newswire
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. has a collaborative research agreement with the Icahn School of Medicine for therapeutic discovery of liver diseases. The company was founded in 1994 and is headquartered in Petah-Tikva, Israel.